Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 16/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481125 | 0.86 | CASR (0.41) | CASRP2RX7ADRB2ADRB3TP53 | |
| SCHEMBL22493429 | 0.76 | CASR (0.46) | CASRADRB2ADRB3TP53MAPT | |
| SCHEMBL22481179 | 0.76 | ADRB1 (0.63) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL22481123 | 0.76 | ADRB1 (0.63) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL9365425 | 0.66 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL29508554 | 0.65 | CASR (0.58) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL9366200 | 0.64 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL21776166 | 0.64 | CASR (0.52) | CASR | |
| SCHEMBL5516663 | 0.64 | CASR (0.58) | CASRCYP2D6 | |
| SCHEMBL23541639 | 0.63 | P2RX7 (0.57) | P2RX7ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137506-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |